Skip to content

FDA Issues Draft Guidance for the Use of Artificial Intelligence (AI) in Medical Devices and Drug Development

 | 

The Food and Drug Administration (FDA) has recently issued two draft guidance documents aimed at providing recommendations for the use of AI in medical devices and drug and biological product development. These guidance documents provide recommendations that seek to support the safe, effective, and transparent use of AI-enabled technologies in healthcare. The press release can be found here.

pic 1

AI in Medical Devices:

The first draft guidance (Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations) introduces a Total Product Life Cycle (TPLC) approach addressing how AI systems maintain their safety and performance over time. This draft guidance provides recommendations for marketing submission content, as well as for the design, development, testing, and post-market monitoring of AI-enabled devices throughout the total product life cycle.

Key content recommendations for marketing submissions include:

  • Device Description
  • User Interface
  • Labeling
  • Risk Assessment
  • Data Management
  • Model Description and Development
  • Performance Validation
  • Device Performance Monitoring
  • Cybersecurity
  • Public Submission Summary

Additionally, the guidance emphasizes strategies to enhance transparency and bias control in AI-enabled devices. These recommendations aim to help developers design, develop, and maintain high-quality devices that prioritize safety and effectiveness.

According to the FDA, “[t]he guidance, if finalized, would be the first guidance to provide comprehensive recommendations for AI-enabled devices throughout the total product lifecycle, providing developers an accessible set of considerations that tie together design, development, maintenance and documentation recommendations to help ensure safety and effectiveness of AI-enabled devices.”

AI in Drug Development:

The second daft guidance (Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products) introduces a risk‐based credibility assessment framework for AI models used in drug development. It emphasizes the importance of maintaining the credibility of AI model outputs throughout their lifecycle and outlines options for sponsors and other interested parties to engage with the Agency on issues related to AI model development.

The risk-based assessment framework includes seven steps:

  • Step 1: Define the Question of Interest
  • Step 2: Define the Context of Use for the AI Model
  • Step 3: Assess the AI Model Risk
  • Step 4: Develop a Plan to Establish AI Model Credibility Within the Context of Use
  • Step 5: Execute the Plan
  • Step 6: Document the Results of the Credibility Assessment Plan and Discuss Deviations From the Plan
  • Step 7: Determine the Adequacy of the AI Model for the Context of Use

A detailed discussion of each step can be found in the corresponding sections of the draft guidance.

The FDA is inviting public comments on these draft guidance documents, with a deadline of April 7, 2025.

Tags

, ,

FDA Issues Draft Guidance for the Use of Artificial Intelligence (AI) in Medical Devices and Drug Development Headshot

Ningxi Sun

Ningxi Sun is an Associate in the firm’s San Diego office. Her practice focuses on patent-related matters in multiple areas of technology, including medical devices, semiconductor devices and processing, metallurgy and materials science, chemicals, and nanotechnology.

Ningxi received her J.D. from the University of San Diego school of Law, where she served as Comment Editor for the San Diego International Law Journal. During law school, she also externed for Judge Gonzalo P. Curiel at the United States District Court for the Southern District of California.

Prior to law school, Ningxi worked as a materials analyst, where she was responsible for materials analysis and failure analysis, and providing technical support for clients in the semiconductor and consumer electronics industries. Ningxi received her B.S. in Materials Chemistry and her M.S. in Materials Engineering.

Ningxi worked as a summer associate at the firm in 2023 and joined the firm in 2024.

View all posts published by Ningxi Sun
By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.
close modal